In vivo, MyD88 deficiency, a key adaptor protein in the activation of NF-κB pathway, restrains glioma development through p38 Mitogen-Activated Protein Kinase (p38-MAPK) signaling pathway [227]. This evidence concerns the gene MAPK14 and central nervous system cancer.